A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf.
Filters
Donepezil effects on sources of cortical rhythms in mild Alzheimer's disease: Responders vs. Non-Responders
2006
NeuroImage
Preserved Fulltext
Katiuscia Sosta for their precious help in the development of the present study. We thank also Prof. Fabrizio Eusebi for his continuous support. ...
We have no conflict of interest with pharmaceutical companies. ...
It should be remarked that none of those papers addressed the specific aim of the present study and focused on the long-term effects of donepezil on cortical EEG rhythms in AD subjects who responded vs ...
doi:10.1016/j.neuroimage.2006.02.015
pmid:16600641
fatcat:nhr4o7yngzc6ddrnhfuccudwjm
Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics
2007
Neuropsychiatric Disease and Treatment
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
Donepezil is the leading compound for the treatment of Alzheimer's disease (AD) in more than 50 countries. ...
Although donepezil represents a non cost-effective treatment, most studies convey that this drug can provide a modest benefit on cognition, behavior, and activities of the daily living in both moderate ...
Donepezil in Alzheimer's disease Most clinical trials with donepezil in AD during the past 10 years have been performed in patients with mild-to-moderate dementia (mAD) (Rogers et al 1996 (Rogers et al ...
pmid:19300564
pmcid:PMC2654795
fatcat:rurc64sbffd2dkn4u44ls4lkqe
Resting state cortical EEG rhythms in Alzheimer's disease
[chapter]
2013
Supplements to Clinical Neurophysiology
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
This review provides an overview of the studies on resting state eyes closed EEG rhythms recorded in amnesic mild cognitive impairment (MCI) and AD subjects. ...
In this line, digital electroencephalography (EEG) allows non-invasive analysis cortical neuronal synchronization as revealed by resting state brain rhythms. ...
On the other hand, the effects of AcetylCholinesterase inhibitors such as tetrahydroaminoacridine and donepezil were tested. ...
doi:10.1016/b978-0-7020-5307-8.00015-6
pmid:24053043
fatcat:efdzlz2hkfb5dkelrj2ztqf7g4
Personalized Management and Treatment of Alzheimer's Disease
2022
Life
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf.
Alzheimer's disease (AD) is a priority health problem with a high cost to society and a large consumption of medical and social resources. ...
The implementation of pharmacogenetics in clinical practice can help optimize the limited therapeutic resources available to treat AD and personalize the use of anti-dementia drugs, in combination with ...
Acknowledgments: The authors would like to thank their collaborators at the International Center of Neuroscience and Genomic Medicine for technical assistance. ...
doi:10.3390/life12030460
pmid:35330211
pmcid:PMC8951963
fatcat:svabmi4wdrdyzeswd5ywxencii
What Electrophysiology Tells Us About Alzheimer's Disease: A Window into the Synchronization and Connectivity of Brain Neurons
2019
Neurobiology of Aging
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
However, current international guidelines do not endorse the use of electroencephalographic (EEG)/magnetoencephalographic (MEG) biomarkers in clinical trials performed in patients with Alzheimer's disease ...
and patients, to probe the effects of AD neuropathology (i.e., brain amyloidosis, tauopathy, and neurodegeneration) on neurophysiological mechanisms underpinning neural excitation/inhibition and neurotransmission ...
of Alzheimer's disease (AD) at the preclinical, prodromal (with objective mild cognitive impairment (MCI) but with aut onomy substantially preserved), and overt dementia stages, based on in-vivo fluid ...
doi:10.1016/j.neurobiolaging.2019.09.008
pmid:31739167
fatcat:4qovqzkklfduvane3tuttfnfem
Sirtuins in Alzheimer's Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics
2019
International Journal of Molecular Sciences
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
Sirtuins are components of the epigenetic machinery, which is disturbed in Alzheimer's disease (AD), contributing to AD pathogenesis. ...
The integration of SIRT2 and APOE variants in bigenic clusters yields 18 haplotypes. ...
Conflicts of Interest: This article did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declare no conflict of interest. ...
doi:10.3390/ijms20051249
fatcat:3hhdssko2rbszpyb4iv4x3le4e
Alzheimer's Disease: Risk Factors and Preventive Strategies
[chapter]
2010
Principles and Practice of Geriatric Psychiatry
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
365, 366
normal pressure hydrocephalus 130
Parkinson's disease 130
galantamine 305
Alzheimer's disease 296-297
cognitive benefits 305
donepezil comparison 306
dosing 305, 314
effect on brain function ...
-369
neuropsychiatric effects 307-308,
318-319
non-responders 306
as part of rehabilitation 814
prescribing and monitoring 306-307
rationale for 304
selection/choice 307
side effects 304-305, 314 ...
doi:10.1002/9780470669600.ch47
fatcat:r3yhydwz5zgzlgr7fxehof64sm
Imaging Markers of Progression in Parkinson's Disease
2018
Movement Disorders Clinical Practice
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
are required to establish a breakthrough in neuroprotective or disease-modifying therapeutics. ...
Parkinson's disease (PD) is the second-most common neurodegenerative disorder after Alzheimer's disease; however, to date, there is no approved treatment that stops or slows down disease progression. ...
In contrast, conversion to dementia in PD might depend on non-dopaminergic, cholinergic and more posterior cortical dysfunctions 27 . ...
doi:10.1002/mdc3.12673
pmid:30637278
pmcid:PMC6277366
fatcat:mseo6ql3xjfh7b56akm6qpdff4
VII Congresso Sindem: Italian Association for the study of Dementia linked to the Italian Neurological Society (SIN)
2012
Journal of Alzheimer's Disease
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf.
Abstracts 43 Diffusion MRI Since the fi rst applications to AD, DT-MRI has shown the ability to detect microscopic WM abnormalities (FA and MD changes), mainly in the corpus callosum, temporal, frontal ...
Conclusions: In LBD, the delta source of cortical EEG rhythms in parieto-occipital regions could be related to a "functional lesion" in regions processing visuo-spatial information. ...
Perfusion SPECT with 99 Tc-ethylene cystine dimer showed hypoperfusion in the frontotemporal
Abstracts 64 Aim: To map the distributed sources of cortical EEG rhythms in LBD respect to AD. ...
doi:10.3233/jad-2012-129000
pmid:22398403
fatcat:zebkyxd3zzat7gsq4vu3eq7zci
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and –specific lesion patterns
2021
Molecular Neurodegeneration
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
Different NPSs occur in different disease stages of AD, but most symptoms appear in the preclinical AD or mild cognitive impairment stage and develop progressively. ...
AbstractNeuropsychiatric symptoms (NPSs) are common in patients with Alzheimer's disease (AD) and are associated with accelerated cognitive impairment and earlier deaths. ...
Acknowledgements We are grateful to Kewei Chen (Banner Alzheimer's Institute) and Chuansheng Chen (University of California, Irvine) for helpful comments on earlier version of this review. ...
doi:10.1186/s13024-021-00456-1
pmid:34099005
pmcid:PMC8186099
fatcat:uoiqeal2krfwxnmtnb5bjrw7re
Diagnosis of Alzheimer's Disease from EEG Signals: Where Are We Standing?
2010
Current Alzheimer Research
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2016; you can also visit the original URL.
The file type is application/pdf.
This paper reviews recent progress in the diagnosis of Alzheimer's disease (AD) from electroencephalograms (EEG). ...
In this paper, several state-of-the-art pre-processing techniques are outlined, for example, based on blind source separation and other non-linear filtering paradigms. ...
One of the major effects is EEG "slowing"; many studies have shown that Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD) causes EEG signals to slow down (see, e.g., [52, 53, 54, 55, 56, 57 ...
doi:10.2174/1567210204558652050
fatcat:ahfknenhb5hmlkp7mkglxtwvum
Imaging the Alzheimer Brain
2011
Journal of Alzheimer's Disease
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
MCI
0.57
Normal vs. Mild AD
0.15
MCI vs. Mild AD
0.20
p-value
P-Tau comparison
33 vs. 34
0.07
33 vs. 44
0.67
34 vs. 44
0.99
Normal vs. MCI
0.05
Normal vs. Mild AD
<0.01
MCI vs. ...
., Effects of Hypoperfusion in Alzheimer's Disease [86]. Shin et al., The Merits of FDDNP-PET Imaging in Alzheimer's [32]. Jensen et al., Research towards tau imaging
). ...
doi:10.3233/jad-2011-0073
pmid:21971448
pmcid:PMC3760773
fatcat:ppczzkpe6rb5tanbygwnzgyr3m
Diagnosis of Alzheimers Disease from EEG Signals: Where Are We Standing?
2010
Current Alzheimer Research
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2016; you can also visit the original URL.
The file type is application/pdf.
This paper reviews recent progress in the diagnosis of Alzheimer's disease (AD) from electroencephalograms (EEG). ...
In this paper, several state-of-the-art pre-processing techniques are outlined, for example, based on blind source separation and other non-linear filtering paradigms. ...
One of the major effects is EEG "slowing"; many studies have shown that Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD) causes EEG signals to slow down (see, e.g., [52, 53, 54, 55, 56, 57 ...
doi:10.2174/156720510792231720
pmid:20455865
fatcat:feusoo2h5jbsnpgczzel4ljwi4
Neuroimaging of Parkinson's disease: Expanding views
2015
Neuroscience and Biobehavioral Reviews
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Advances in molecular and structural and functional neuroimaging are rapidly expanding the complexity of neurobiological understanding of Parkinson's disease (PD). ...
Neuropathology of PD will be discussed centered on Braak's staging of PD, which describes the progression of pathological abnormalities in regions throughout the brain (section 2.3). ...
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of ...
doi:10.1016/j.neubiorev.2015.09.007
pmid:26409344
pmcid:PMC4763948
fatcat:66ruxnmpyjdoplebvahzyibydq
Prevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges
2014
Frontiers in Pharmacology
Preserved Fulltext
The Internet Archive has a preservation copy of this work in our general collections.
The file type is application/pdf.
Aged dogs spontaneously develop many features of human aging and Alzheimer's disease (AD) including cognitive decline and neuropathology. ...
However, overall, using the dog as a preclinical model for testing preventive approaches for AD may complement work in rodents and non-human primates. ...
In particular, AD patients with mild to moderate dementia who were treated with 80 mg/day atorvastatin had significantly improved scores on one measure of cognition Alzheimer's Disease Assessment Scale-Cognitive ...
doi:10.3389/fphar.2014.00047
pmid:24711794
pmcid:PMC3968758
fatcat:caiie5cfbfccrg7v3e35wwt3mq
« Previous
Showing results 1 — 15 out of 129 results